NASDAQ:CBIO

Catalyst Biosciences Competitors

$4.32
-0.07 (-1.59 %)
(As of 07/23/2021 03:08 PM ET)
Add
Compare
Today's Range
$4.26
$4.39
50-Day Range
$4.10
$4.65
52-Week Range
$4.05
$7.55
Volume690 shs
Average Volume472,967 shs
Market Capitalization$135.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02

Catalyst Biosciences (NASDAQ:CBIO) Vs. AMGN, GILD, REGN, VRTX, BIIB, and ALXN

Should you be buying CBIO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Catalyst Biosciences, including Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for Amgen and Catalyst Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen291402.48
Catalyst Biosciences00503.00

Amgen presently has a consensus price target of $256.1905, indicating a potential upside of 3.74%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 4.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Amgen and Catalyst Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$25.42 billion5.59$7.26 billion$16.6014.89
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47

Amgen has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Catalyst Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen28.16%93.84%14.85%
Catalyst Biosciences-1,233.58%-77.89%-66.42%

Summary

Amgen beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 76.8% of Gilead Sciences shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Catalyst Biosciences and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalyst Biosciences-1,233.58%-77.89%-66.42%
Gilead Sciences1.18%51.91%14.95%

Volatility & Risk

Catalyst Biosciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Catalyst Biosciences and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalyst Biosciences00503.00
Gilead Sciences091102.55

Catalyst Biosciences presently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Gilead Sciences has a consensus target price of $101.9524, indicating a potential upside of 47.67%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Catalyst Biosciences is more favorable than Gilead Sciences.

Valuation & Earnings

This table compares Catalyst Biosciences and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47
Gilead Sciences$24.69 billion3.51$123 million$7.099.73

Gilead Sciences has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 82.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Catalyst Biosciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalyst Biosciences-1,233.58%-77.89%-66.42%
Regeneron Pharmaceuticals43.53%35.43%22.84%

Risk and Volatility

Catalyst Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Catalyst Biosciences and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalyst Biosciences00503.00
Regeneron Pharmaceuticals051102.69

Catalyst Biosciences currently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Regeneron Pharmaceuticals has a consensus target price of $659.0588, indicating a potential upside of 12.65%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Catalyst Biosciences and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47
Regeneron Pharmaceuticals$8.50 billion7.35$3.51 billion$28.6620.45

Regeneron Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Catalyst Biosciences on 11 of the 14 factors compared between the two stocks.

Catalyst Biosciences (NASDAQ:CBIO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

71.3% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 89.9% of Vertex Pharmaceuticals shares are held by institutional investors. 4.0% of Catalyst Biosciences shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Catalyst Biosciences and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47
Vertex Pharmaceuticals$6.21 billion8.37$2.71 billion$9.0322.21

Vertex Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Catalyst Biosciences and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalyst Biosciences00503.00
Vertex Pharmaceuticals151702.70

Catalyst Biosciences currently has a consensus target price of $12.4367, indicating a potential upside of 187.89%. Vertex Pharmaceuticals has a consensus target price of $264.4444, indicating a potential upside of 31.98%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Catalyst Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Catalyst Biosciences and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalyst Biosciences-1,233.58%-77.89%-66.42%
Vertex Pharmaceuticals43.06%29.61%21.74%

Summary

Vertex Pharmaceuticals beats Catalyst Biosciences on 10 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Biogen and Catalyst Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen23.89%42.04%18.44%
Catalyst Biosciences-1,233.58%-77.89%-66.42%

Valuation & Earnings

This table compares Biogen and Catalyst Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$13.44 billion3.64$4.00 billion$33.709.66
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47

Biogen has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Institutional & Insider Ownership

83.3% of Biogen shares are held by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 4.0% of Catalyst Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Biogen and Catalyst Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen0131702.57
Catalyst Biosciences00503.00

Biogen currently has a consensus price target of $385.3252, indicating a potential upside of 18.74%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Biogen.

Summary

Biogen beats Catalyst Biosciences on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Catalyst Biosciences (NASDAQ:CBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Catalyst Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$6.07 billion6.65$603.40 million$11.6015.73
Catalyst Biosciences$20.95 million6.46$-56,240,000.00($2.93)-1.47

Alexion Pharmaceuticals has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Catalyst Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals014402.22
Catalyst Biosciences00503.00

Alexion Pharmaceuticals currently has a consensus price target of $158.4444, indicating a potential downside of 13.18%. Catalyst Biosciences has a consensus price target of $12.4367, indicating a potential upside of 187.89%. Given Catalyst Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Biosciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Catalyst Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals10.89%23.43%15.06%
Catalyst Biosciences-1,233.58%-77.89%-66.42%

Institutional and Insider Ownership

82.9% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.3% of Catalyst Biosciences shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Catalyst Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats Catalyst Biosciences on 10 of the 14 factors compared between the two stocks.


Catalyst Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$247.19-1.0%$142.02 billion$25.42 billion20.48Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$69.01-0.5%$86.55 billion$24.69 billion300.06Upcoming Earnings
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.0$586.02-0.1%$62.43 billion$8.50 billion16.59Analyst Report
Short Interest Decrease
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.3$200.53-2.2%$51.91 billion$6.21 billion19.10Upcoming Earnings
Analyst Downgrade
Biogen logo
BIIB
Biogen
2.1$325.41-0.3%$48.99 billion$13.44 billion17.07Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.6$182.50-0.0%$40.34 billion$6.07 billion59.64Upcoming Earnings
Seagen logo
SGEN
Seagen
1.6$144.48-0.8%$26.22 billion$2.18 billion40.02Upcoming Earnings
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.4$182.93-0.6%$21.50 billion$492.85 million-24.26
Exact Sciences logo
EXAS
Exact Sciences
1.8$117.76-0.2%$20.20 billion$1.49 billion-23.50Upcoming Earnings
Incyte logo
INCY
Incyte
2.1$79.29-0.8%$17.44 billion$2.67 billion36.54Analyst Upgrade
Unusual Options Activity
Analyst Revision
Novavax logo
NVAX
Novavax
1.6$203.35-3.2%$15.07 billion$475.60 million-21.96Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.2$76.96-1.9%$14.06 billion$1.86 billion18.96Upcoming Earnings
Repligen logo
RGEN
Repligen
1.6$208.62-1.3%$11.45 billion$366.26 million143.88Upcoming Earnings
Insider Selling
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.4$98.81-0.7%$9.34 billion$1.05 billion24.10Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.8$185.01-0.4%$8.29 billion$1.48 billion20.44Analyst Downgrade
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.7$43.22-1.7%$6.15 billion$267.59 million38.25
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.01-1.4%$5.36 billion$729 million-10.77Insider Selling
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$16.74-1.2%$5.25 billion$987.54 million83.70
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.52-1.5%$3.98 billion$320,000.00-8.88
Alkermes logo
ALKS
Alkermes
1.2$24.41-1.1%$3.92 billion$1.04 billion-40.68Upcoming Earnings
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$64.52-1.3%$3.46 billion$1.56 billion8.99Upcoming Earnings
Short Interest Increase
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$17.39-2.4%$3.09 billion$17.81 million-14.49Analyst Upgrade
News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$32.05-0.4%$2.47 billion$638.60 million-15.63
OPKO Health logo
OPK
OPKO Health
1.8$3.67-0.3%$2.46 billion$1.44 billion19.32Upcoming Earnings
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$8.87-1.5%$2.36 billion$260.89 million-9.14News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$13.10-0.8%$2.12 billion$389.52 million14.72News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$122.51-0.2%$2.04 billion$186.42 million53.27Upcoming Earnings
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.5$41.89-5.8%$1.95 billion$7.42 million-22.89Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$89.20-1.9%$1.48 billionN/A-6.34
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$9.96-2.0%$1.43 billion$118.19 million-11.32Analyst Downgrade
News Coverage
Innoviva logo
INVA
Innoviva
1.4$13.41-0.0%$1.36 billion$336.79 million5.91
Codexis logo
CDXS
Codexis
1.5$20.97-1.1%$1.35 billion$69.06 million-51.15
Agenus logo
AGEN
Agenus
1.4$5.62-0.7%$1.25 billion$88.17 million-5.46Analyst Downgrade
ImmunoGen logo
IMGN
ImmunoGen
1.5$5.58-0.4%$1.12 billion$132.30 million-19.93Upcoming Earnings
MannKind logo
MNKD
MannKind
1.4$4.42-1.4%$1.10 billion$65.14 million-17.00Analyst Upgrade
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$9.51-2.1%$1.09 billion$46.55 million-11.74
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$19.57-0.8%$1.09 billion$248.17 million34.33Upcoming Earnings
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.9$14.53-3.2%$1.01 billion$64.89 million-15.79Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.13-1.2%$702.76 million$108.62 million-58.99News Coverage
Curis logo
CRIS
Curis
1.7$7.42-3.8%$679.23 million$10.84 million-14.84Analyst Downgrade
Short Interest Increase
Verastem logo
VSTM
Verastem
1.4$3.34-4.2%$574.21 million$88.52 million-12.37Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$16.84-2.1%$558.41 million$312.69 million-2.50Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.29-1.2%$539.92 million$109.33 million-2.76
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.89-2.7%$511.35 million$164.52 million-1.32
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.5$3.43-3.5%$495.26 million$24 million-26.38Upcoming Earnings
Analyst Downgrade
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.4$2.25-2.2%$484.92 million$150,000.00-5.62
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$12.53-2.5%$455.34 million$230,000.00-0.56Positive News
Geron logo
GERN
Geron
1.5$1.32-1.9%$418.92 million$250,000.00-4.70News Coverage
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
1.9$7.26-0.7%$407.29 million$18.84 million-3.26Insider Buying
News Coverage
Arctos NorthStar Acquisition logo
ANAC
Arctos NorthStar Acquisition
0.6$9.71-0.1%$383.84 millionN/A0.00News Coverage
This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.